UroGen Pharma Past Earnings Performance
Past criteria checks 0/6
UroGen Pharmahan disminuido a un ritmo medio anual de -5.4%, mientras que en la industria Biotechs los ingresos han sido de growing a 17.4% anuales. Los ingresos han sido growing a una tasa media anual de 62.1%.
Key information
-2.7%
Earnings growth rate
3.9%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 58.4% |
| Return on equity | n/a |
| Net Margin | -123.6% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
UroGen: All Eyes On UGN-102
Mar 18UroGen Pharma Ltd. (NASDAQ:URGN) Just Released Its Annual Results And Analysts Are Updating Their Estimates
Mar 17
UroGen Pharma Ltd. (NASDAQ:URGN) Looks Inexpensive But Perhaps Not Attractive Enough
Jan 18UroGen gets FDA nod for extending duration of Jelmyto admixture
Sep 28UroGen Pharma (NASDAQ:URGN) Is In A Good Position To Deliver On Growth Plans
Mar 09We're Not Very Worried About UroGen Pharma's (NASDAQ:URGN) Cash Burn Rate
Nov 04Is UroGen Pharma (NASDAQ:URGN) In A Good Position To Invest In Growth?
Jun 14What Does The Future Hold For UroGen Pharma Ltd. (NASDAQ:URGN)? These Analysts Have Been Cutting Their Estimates
May 18Revenue & Expenses BreakdownBeta
How UroGen Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 83 | -102 | 93 | 46 |
| 30 Sep 23 | 77 | -105 | 90 | 49 |
| 30 Jun 23 | 73 | -109 | 88 | 52 |
| 31 Mar 23 | 68 | -112 | 86 | 53 |
| 31 Dec 22 | 64 | -110 | 83 | 53 |
| 30 Sep 22 | 62 | -109 | 83 | 52 |
| 30 Jun 22 | 58 | -114 | 85 | 50 |
| 31 Mar 22 | 54 | -113 | 87 | 50 |
| 31 Dec 21 | 48 | -111 | 88 | 48 |
| 30 Sep 21 | 40 | -113 | 88 | 47 |
| 30 Jun 21 | 32 | -111 | 89 | 45 |
| 31 Mar 21 | 19 | -117 | 90 | 41 |
| 31 Dec 20 | 12 | -128 | 90 | 41 |
| 30 Sep 20 | 4 | -137 | 88 | 48 |
| 30 Jun 20 | 0 | -130 | 80 | 48 |
| 31 Mar 20 | 0 | -121 | 69 | 50 |
| 31 Dec 19 | 0 | -105 | 60 | 49 |
| 30 Sep 19 | 0 | -90 | 46 | 38 |
| 30 Jun 19 | 0 | -88 | 42 | 38 |
| 31 Mar 19 | 1 | -84 | 39 | 37 |
| 31 Dec 18 | 1 | -76 | 32 | 35 |
| 30 Sep 18 | 1 | -62 | 30 | 32 |
| 30 Jun 18 | 9 | -42 | 22 | 28 |
| 31 Mar 18 | 9 | -30 | 14 | 24 |
| 31 Dec 17 | 8 | -21 | 9 | 19 |
| 30 Sep 17 | 25 | 2 | 7 | 14 |
| 30 Jun 17 | 18 | -7 | 8 | 12 |
| 31 Mar 17 | 18 | -4 | 6 | 10 |
| 31 Dec 16 | 18 | -4 | 6 | 10 |
| 30 Sep 16 | 0 | -24 | 6 | 14 |
| 31 Mar 16 | 0 | -16 | 3 | 11 |
| 31 Dec 15 | 0 | -14 | 2 | 11 |
| 30 Sep 15 | 0 | -7 | 1 | 5 |
| 31 Dec 14 | 0 | -5 | 1 | 3 |
Beneficios de calidad: URGN actualmente no es rentable.
Creciente margen de beneficios: URGN actualmente no es rentable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Tendencia de beneficios: URGN no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 5.4% al año.
Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de URGN en el último año con su media de 5 años, ya que actualmente no es rentable.
Beneficios vs. Industria: URGN no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el del sector Biotechs (-42.7%).
Return on Equity
Alto ROE: URGNEl pasivo de la empresa supera su activo, por lo que es difícil calcular su Rentabilidad de los fondos propios.